Last checked at 
30 Apr 2018 10:25
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Amendments to the Top Ten Quoted Investments have been made to the 'Portfolio Update' announcement released on Friday, 27 April 2018 at 12:58 under RNS No 4257M.
All other details remain unchanged.
The full amended text is shown below.
Portfolio Update as at 31 March 2018
Net Assets | £219m |
Net Assets per share | 584p |
Share price | 548p |
Total value of unquoted investments | £21m |
Total number of portfolio companies | 90 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Celgene | 6.0 |
Shire | 4.8 |
Array | 4.5 |
Neurocrine | 4.2 |
Biogen | 4.1 |
Regeneron | 4.0 |
Genmab | 3.9 |
Sage | 3.7 |
Vertex | 3.6 |
Gilead | 3.2 |
----------- | |
Total | 42.0 |
Geographical Allocation | % NAV |
US & Canada | 83 |
Europe & UK | 17 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 91 |
Unquoted | 9 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 36 |
Mid Cap =USD1-10BN | 37 |
Small Cap | 27 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 42 |
CNS | 18 |
Rare diseases | 11 |
Inflammation | 7 |
Ophthalmology | 6 |
Infectious Diseases | 4 |
Metabolic | 3 |
Medtech | 3 |
Other | 6 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
30 APRIL 2018